Ashwell receptor reduces mortality during sepsis

In research that solves the longest-standing mystery in glycobiology – a field that studies complex sugar chains called glycans – researchers at the University of California, San Diego School of Medicine have discovered that a molecule in the liver of all animals, called the Ashwell receptor, is critical in helping the body fight off the abnormal and lethal blood clotting caused by bacterial infection. Until now, it was suspected that this receptor might serve to remove abnormal proteins from circulation, but it wasn’t understood which proteins were affected or what biological purpose this receptor served.

The study, published online in advance of publication in the June issue of Nature Medicine, shows that the Ashwell receptor plays an essential role in reducing coagulation abnormalities during infection and sepsis, significantly improving the probability of survival.

Sepsis, a life-threatening complication of bacterial infection in the blood, remains a major cause of death worldwide, according to the study’s principal investigator, Jamey Marth, Ph.D., UCSD Professor of Cellular and Molecular Medicine and Investigator with the Howard Hughes Medical Institute. One of the major factors contributing to death in patients with sepsis is a condition called disseminated intravascular coagulation, which accelerates blood clotting.

UCSD researchers discovered that a protective response, triggered by the Ashwell receptor in the liver, limits this lethal side effect by reducing the levels of circulating blood coagulation factors, including platelets.

The bacterial pathogen Streptococcus pneumoniae (pneumococcus) is a leading cause of sepsis, especially in the young, the elderly and the immuno-compromised. The pneumococcus makes an enzyme called sialidase, which removes sugar molecules called sialic acid from host cells, and helps facilitate spread of the pathogen through the body. Using a mouse model of sepsis, the researchers found that the pneumococcal sialidase also removes sialic acid from circulating host factors involved in blood coagulation, including platelets and a glycoprotein called von Willebrand Factor (vWF). When this occurs, the Ashwell receptor recognizes the change in the glycoprotein structure and removes those pro-coagulation factors from circulation before they can cause increased blood coagulation.

The researchers made a breakthrough when they discovered that platelet counts and vWF that are reduced during pneumococcal infection remained high and unchanged in the absence of the Ashwell receptor. Pivotal results came when mice lacking the Ashwell receptor developed severe tissue and organ damage due to increased coagulation and died at significantly higher frequency and more rapidly than expected.

“This finding contradicts the prevailing notion that the low platelet count of sepsis is due to the consumption of coagulation factors caused by the pathogen and is therefore harmful,” said Marth. “Rather, this low platelet count is due an adaptive response by the Ashwell receptor that is beneficial by reducing tissue damage and organ failure and thereby improving the chance of survival.”

More than 35 years ago, researcher Gilbert Ashwell and colleagues discovered that the liver controls the removal of proteins in the bloodstream. The Ashwell receptor –also known as the hepatic asialoglycoprotein receptor – was the first glycan-binding receptor, or lectin, ever discovered in animals.

“The Ashwell receptor is ‘turned on’ after birth, and this was a clue that it is needed for environmental and pathogenic challenges,” said Marth.

“This research provides a whole new way of thinking about coagulation problems in sepsis produced by pneumococcus and related pathogens” said Victor Nizet, M.D., UCSD professor of pediatrics and pharmacy whose laboratory assisted in the study. “Drugs designed to support the normal capabilities of the Ashwell receptor in the liver would represent a new approach to limiting mortality in these life-threatening conditions.”

Source: University of California - San Diego

Related stories:

Key found to breakthrough drug for clot victims
A team of researchers at Oregon Health & Science University and Washington University in St. Louis have described for the first time the mechanism that gives a mutant enzyme molecule that they have engineered – and patented – the potential to become a breakthrough drug for treating heart attacks and strokes.
Scientists studying sepsis in mice find potential drug targets for deadly disease
Scientists at The Scripps Research Institute have uncovered a connection between blood coagulation and the immune system that may have important implications for people with sepsis, a severe and difficult to treat disease that kills tens of thousands of Americans a year.
Blood clotting protein may inhibit spinal cord regeneration
Fibrinogen, a blood-clotting protein found in circulating blood, has been found to inhibit the growth of central nervous system neuronal cells, a process that is necessary for the regeneration of the spinal cord after traumatic injury. The findings by researchers at the University of California, San Diego (UCSD) School of Medicine, may explain why the human body is unable to repair itself after most spinal cord injuries.
Inhibiting blood to save the brain
A fibrous protein called fibrinogen, found in circulating blood and important in blood clotting, can promote multiple sclerosis (MS) when it leaks from the blood into the brain, triggering inflammation that leads to MS-related nerve damage. Researchers at the University of California, San Diego (UCSD) School of Medicine have identified a fibrin-derived peptide that inhibits this specific inflammation process in mouse models of MS, reducing MS symptoms.
Protein shown to play a key role in normal development of nervous system
A protein that enables nerve cells to communicate with each other plays a key role in controlling the developing nervous system. Research into how that protein helps precise connections to form among nerve cells may provide a basis for eventual treatments for patients who suffer injuries to their nervous system, including spinal cord injury.
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute.
New research may help to design better gene therapy vectors
(PhysOrg.com) -- Research published by scientists from the University of Reading may offer an insight into ways of making safer and more specific gene therapy vectors. The research, published in the journal Nature Structural and Molecular Biology, describes the structure of the viral fusion protein gp64, which is involved in the mechanism which viruses use to invade host cells. In the past, Bacloviruses have been suggested as possible gene therapy vectors due to the way in which they enter host cells, but there has been little evidence which explain these properties up to now.
Battling cancer, one cell at a time
New research suggests that the identification and examination of key cell signaling events required for initiation and progression of cancer might be best accomplished at the single cell level. The research, published by Cell Press in the October issue of the journal Cancer Cell, provides new insight that may lead to better diagnosis and treatment of some complex cancers.

News discussion:

Medicine & Health news